Apyx Medical Corp
جودة البيانات: 100%
APYX
NASDAQ
Manufacturing
Measuring & Analyzing Instruments
KWD 3.96
▼
KWD 0.04
(-1.00%)
القيمة السوقية: 166.06 M
السعر
KWD 3.97
القيمة السوقية
166.06 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Revenue grew 2.16% annually over 5 years — modest growth
Debt/Equity of 6.41 — high leverage
Negative free cash flow of -9.12 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 7.70%
Capital efficient — spends only 2.11% of revenue on capex
النمو
Revenue Growth (5Y)
2.16%
أعلى من متوسط القطاع (1.82%)
Revenue (1Y)9.86%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-171.15%
أقل من متوسط القطاع (-54.01%)
ROIC-10.83%
Net Margin-21.22%
Op. Margin-12.20%
الأمان
Debt / Equity
6.41
أعلى من متوسط القطاع (0.30)
Current Ratio4.44
Interest Coverage-1.15
التقييم
PE (TTM|NTM)
-14.81 | -14.04
أقل من متوسط القطاع (-1.49)
P/B Ratio28.40
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -14.8 | -1.5 |
| P/B | 28.4 | 1.6 |
| ROE % | -171.2 | -54.0 |
| Net Margin % | -21.2 | -41.5 |
| Rev Growth 5Y % | 2.2 | 1.8 |
| D/E | 6.4 | 0.3 |
السعر المستهدف للمحللين
5 محللين
Buy
الحالي
KWD 3.96
المستهدف
KWD 6.40
KWD 6.00
KWD 6.00
KWD 8.00
التوقعات
مكرر الربحية المستقبلي
-14.04
ربحية السهم المستقبلية
-KWD 0.28
الإيرادات المقدّرة
63.78 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 0.28
-KWD 0.35 – -KWD 0.20
|
63.78 M | 5 |
| FY2026 |
-KWD 0.32
-KWD 0.36 – -KWD 0.30
|
57.84 M | 5 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.09
-KWD 0.10 – -KWD 0.07
|
13.11 M | 5 |
| 2026 Q1 |
-KWD 0.11
-KWD 0.15 – -KWD 0.06
|
10.76 M | 5 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.06 | -KWD 0.03 | +46.4% |
| Q32025 | -KWD 0.10 | -KWD 0.05 | +51.2% |
| Q22025 | -KWD 0.09 | -KWD 0.09 | +3.6% |
| Q12025 | -KWD 0.12 | -KWD 0.10 | +16.7% |
ETFs Holding This Stock
BRSIX
BRSIX
0.12% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 9.86% | Revenue Growth (3Y) | 0.47% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 2.16% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 52.84 M | Net Income (TTM) | -11.21 M |
| ROE | -171.15% | ROA | -19.40% |
| Gross Margin | 62.53% | Operating Margin | -12.20% |
| Net Margin | -21.22% | Free Cash Flow (TTM) | -9.12 M |
| ROIC | -10.83% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 6.41 | Current Ratio | 4.44 |
| Interest Coverage | -1.15 | Asset Turnover | 0.91 |
| Working Capital | 37.81 M | Tangible Book Value | 5.85 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -14.81 | Forward P/E | -14.04 |
| P/B Ratio | 28.40 | P/S Ratio | 3.14 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 2.60 | Fwd Earnings Yield | N/A |
| FCF Yield | -5.49% | ||
| Market Cap | 166.06 M | Enterprise Value | 178.43 M |
| Per Share | |||
| EPS (Diluted TTM) | N/A | Revenue / Share | 1.26 |
| FCF / Share | -0.22 | OCF / Share | -0.19 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 2.11% | FCF Conversion | 81.30% |
| SBC-Adj. FCF | -11.61 M | Growth Momentum | 7.70 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 52.84 M | 48.10 M | 52.35 M | 44.51 M | 48.52 M |
| Net Income | -11.21 M | -23.46 M | -18.71 M | -23.18 M | -15.17 M |
| EPS (Diluted) | — | — | -0.54 | -0.67 | -0.44 |
| Gross Profit | 33.04 M | 29.36 M | 33.76 M | 29.13 M | 33.60 M |
| Operating Income | -6.45 M | -18.85 M | -17.26 M | -23.56 M | -14.45 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 3.37 M | 5.08 M | 4.84 M | 4.54 M | 4.32 M |
| SG&A Expenses | 15.80 M | 18.86 M | 22.20 M | 20.48 M | 18.62 M |
| D&A | 655,000.0 | 599,000.0 | 692,000.0 | 890,000.0 | 903,000.0 |
| Interest Expense | 5.59 M | 5.91 M | 2.48 M | 15,000.0 | 10,000.0 |
| Income Tax | 270,000.0 | 252,000.0 | -2.43 M | 367,000.0 | 380,000.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 66.84 M | 64.84 M | 79.24 M | 51.78 M | 68.72 M |
| Total Liabilities | 52.01 M | 50.51 M | 52.32 M | 13.98 M | 14.71 M |
| Shareholders' Equity | 14.54 M | 14.21 M | 26.70 M | 37.58 M | 53.70 M |
| Total Debt | 37.50 M | 37.50 M | 33.19 M | — | — |
| Cash & Equivalents | 31.74 M | 31.74 M | 43.65 M | 10.19 M | 30.87 M |
| Current Assets | 58.47 M | 56.44 M | 70.36 M | 42.97 M | 60.74 M |
| Current Liabilities | 11.70 M | 10.72 M | 12.74 M | 11.85 M | 13.21 M |
{"event":"ticker_viewed","properties":{"ticker":"APYX","listing_kind":"stock","pathname":"/stocks/apyx","exchange":"NASDAQ","country":"US"}}